{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:10Z","timestamp":1793939410982,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00415-025-13425-1","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:22:55Z","timestamp":1759846975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study"],"prefix":"10.1007","volume":"272","author":[{"given":"Abdulkadir","family":"Tun\u00e7","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0264-7284","authenticated-orcid":false,"given":"Emine Rabia","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gomez Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Gluscevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitoria","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Zarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Bakirtzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Casallas-Vanegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Sefero\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"3","key":"13425_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol 22(3):268\u2013282. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"13425_CR2","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","volume":"270","author":"S Jarius","year":"2023","unstructured":"Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K et al (2023) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis optica study group (NEMOS). Part I: diagnosis and differential diagnosis. J Neurol 270:3341\u20133368. https:\/\/doi.org\/10.1007\/s00415-023-11634-0","journal-title":"J Neurol"},{"issue":"9451","key":"13425_CR3","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106\u20132112. https:\/\/doi.org\/10.1016\/S0140-6736(04)17551-X","journal-title":"Lancet"},{"issue":"5","key":"13425_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz059","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D, Majed M, Elsone L, Hamid S et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142(5):1310\u20131323. https:\/\/doi.org\/10.1093\/brain\/awz059","journal-title":"Brain"},{"issue":"3","key":"13425_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211032334","volume":"7","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Lopez PA, Pettinicchi JP et al (2021) Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina. Mult Scler 7(3):20552173211032334. https:\/\/doi.org\/10.1177\/20552173211032334","journal-title":"Mult Scler"},{"key":"13425_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ et al (2022) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol 13:885218. https:\/\/doi.org\/10.3389\/fneur.2022.885218","journal-title":"Front Neurol"},{"issue":"21","key":"13425_CR7","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90(21):e1858\u2013e1869. https:\/\/doi.org\/10.1212\/WNL.0000000000005560","journal-title":"Neurology"},{"issue":"4","key":"13425_CR8","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/acn3.51750","volume":"10","author":"I Lotan","year":"2023","unstructured":"Lotan I, Romanow G, Salky R et al (2023) Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Ann Clin Transl Neurol 10(4):664\u2013667. https:\/\/doi.org\/10.1002\/acn3.51750","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"13425_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflammation"},{"key":"13425_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.122909","volume":"458","author":"N Molazadeh","year":"2024","unstructured":"Molazadeh N, Bilodeau PA, Salky R, Clark K, Kaplin AI, Levy M et al (2024) Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). J Neurol Sci 458:122909. https:\/\/doi.org\/10.1016\/j.jns.2024.122909","journal-title":"J Neurol Sci"},{"issue":"12","key":"13425_CR11","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall M, Raza N, Everett R, Roca-Fernandez A et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","journal-title":"Brain"},{"issue":"2","key":"13425_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VS et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89(2):127\u2013137. https:\/\/doi.org\/10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13425_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000225","volume":"3","author":"M Sep\u00falveda","year":"2016","unstructured":"Sep\u00falveda M, Armangu\u00e9 T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C et al (2016) Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 3:e225. https:\/\/doi.org\/10.1212\/NXI.0000000000000225","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"13425_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/antib13020043","volume":"13","author":"P Gklinos","year":"2024","unstructured":"Gklinos P, Dobson R (2024) Myelin oligodendrocyte glycoprotein-antibody associated disease: an updated review of the clinical spectrum, pathogenetic mechanisms and therapeutic management. Antibodies 13(2):43. https:\/\/doi.org\/10.3390\/antib13020043","journal-title":"Antibodies"},{"issue":"5","key":"13425_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200275","volume":"11","author":"CE Moseley","year":"2024","unstructured":"Moseley CE, Virupakshaiah A, Forsthuber TG, Steinman L, Waubant E, Zamvil SS (2024) MOG CNS autoimmunity and MOGAD. Neurol Neuroimmunol Neuroinflamm 11(5):e200275. https:\/\/doi.org\/10.1212\/NXI.0000000000200275","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"13425_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103693","volume":"24","author":"BP Trewin","year":"2025","unstructured":"Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S (2025) MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev 24(1):103693. https:\/\/doi.org\/10.1016\/j.autrev.2024.103693","journal-title":"Autoimmun Rev"},{"key":"13425_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102522","volume":"46","author":"X Ma","year":"2020","unstructured":"Ma X, Kermode AG, Hu X, Qiu W (2020) Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy. Mult Scler Relat Disord 46:102522. https:\/\/doi.org\/10.1016\/j.msard.2020.102522","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"13425_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"issue":"8","key":"13425_CR19","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1007\/s00415-024-12452-8","volume":"271","author":"S Arnett","year":"2024","unstructured":"Arnett S, Chew SH, Leitner U et al (2024) Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. J Neurol 271(8):4794\u20134812. https:\/\/doi.org\/10.1007\/s00415-024-12452-8","journal-title":"J Neurol"},{"issue":"8","key":"13425_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1177\/1352458516674366","volume":"23","author":"SM Kim","year":"2017","unstructured":"Kim SM, Waters P, Woodhall M et al (2017) Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G. Mult Scler 23(8):1104\u20131111. https:\/\/doi.org\/10.1177\/1352458516674366","journal-title":"Mult Scler"},{"issue":"5","key":"13425_CR21","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","volume":"266","author":"R Wynford-Thomas","year":"2019","unstructured":"Wynford-Thomas R, Jacob A, Tomassini V (2019) Neurological update: MOG antibody disease. J Neurol 266(5):1280\u20131286. https:\/\/doi.org\/10.1007\/s00415-018-9122-2","journal-title":"J Neurol"},{"key":"13425_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103401","volume":"58","author":"GG Luetic","year":"2022","unstructured":"Luetic GG, Menichini ML, Vrech C et al (2022) Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. does sex or phenotype make the difference in the association with poor prognosis? Mult Scler Relat Disord 58:103401. https:\/\/doi.org\/10.1016\/j.msard.2021.103401","journal-title":"Mult Scler Relat Disord"},{"issue":"Pt 6","key":"13425_CR23","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135(Pt 6):1834\u20131849. https:\/\/doi.org\/10.1093\/brain\/aws109","journal-title":"Brain"},{"issue":"5","key":"13425_CR24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","volume":"267","author":"E Carnero Contentti","year":"2020","unstructured":"Carnero Contentti E, Daccach Marques V, Soto de Castillo I et al (2020) Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a latin American cohort. J Neurol 267(5):1260\u20131268. https:\/\/doi.org\/10.1007\/s00415-020-09699-2","journal-title":"J Neurol"},{"issue":"4","key":"13425_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000468","volume":"5","author":"MA Mealy","year":"2018","unstructured":"Mealy MA, Kessler RA, Rimler Z et al (2018) Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurol Neuroimmunol Neuroinflamm 5(4):e468. https:\/\/doi.org\/10.1212\/NXI.0000000000000468","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13425_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104611","volume":"72","author":"E Carnero Contentti","year":"2023","unstructured":"Carnero Contentti E, L\u00f3pez PA, Criniti J et al (2023) Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from latin America. Mult Scler Relat Disord 72:104611. https:\/\/doi.org\/10.1016\/j.msard.2023.104611","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"13425_CR27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000504","volume":"5","author":"I Kleiter","year":"2018","unstructured":"Kleiter I, Gahlen A, Borisow N et al (2018) Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 5(6):e504. https:\/\/doi.org\/10.1212\/NXI.0000000000000504","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"13425_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O et al (2024) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica study group (NEMOS). Part II: attack therapy and long-term management [published correction appears in J Neurol. 2024 Jun; 271(6):3702-3707. 10.1007\/s00415-024-12288-2]. J Neurol 271(1):141\u2013176. https:\/\/doi.org\/10.1007\/s00415-023-11910-z","journal-title":"J Neurol"},{"issue":"4","key":"13425_CR29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","volume":"89","author":"M Bonnan","year":"2018","unstructured":"Bonnan M, Valentino R, Debeugny S et al (2018) Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 89(4):346\u2013351. https:\/\/doi.org\/10.1136\/jnnp-2017-316286","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"13425_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S, Paul F, Franciotta D et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306(1\u20132):82\u201390. https:\/\/doi.org\/10.1016\/j.jns.2011.03.038","journal-title":"J Neurol Sci"},{"issue":"4","key":"13425_CR31","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1212\/WNL.0000000000207443","volume":"101","author":"S Demuth","year":"2023","unstructured":"Demuth S, Collongues N, Audoin B et al (2023) Rituximab de-escalation in patients with neuromyelitis optica spectrum disorder. Neurology 101(4):e438\u2013e450. https:\/\/doi.org\/10.1212\/WNL.0000000000207443","journal-title":"Neurology"},{"key":"13425_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.msard.2019.02.023","volume":"30","author":"S Salama","year":"2019","unstructured":"Salama S, Pardo S, Levy M (2019) Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 30:231\u2013235. https:\/\/doi.org\/10.1016\/j.msard.2019.02.023","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"13425_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055392","volume":"11","author":"S Huda","year":"2021","unstructured":"Huda S, Whittam D, Jackson R et al (2021) Predictors of relapse in MOG antibody associated disease: a cohort study. BMJ Open 11(11):e055392. https:\/\/doi.org\/10.1136\/bmjopen-2021-055392","journal-title":"BMJ Open"},{"issue":"6","key":"13425_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/jnnp-2024-334764","volume":"96","author":"V H\u00e4u\u00dfler","year":"2025","unstructured":"H\u00e4u\u00dfler V, Trebst C, Engels D et al (2025) Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD. J Neurol Neurosurg Psychiatry 96(6):582\u2013592. https:\/\/doi.org\/10.1136\/jnnp-2024-334764","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"13425_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209624","volume":"103","author":"R Deschamps","year":"2024","unstructured":"Deschamps R, Guillaume J, Ciron J et al (2024) Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults: the MOGADOR2 study. Neurology 103(3):e209624. https:\/\/doi.org\/10.1212\/WNL.0000000000209624","journal-title":"Neurology"},{"key":"13425_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1559118","volume":"16","author":"J Zhou","year":"2025","unstructured":"Zhou J, Yang X, Wang X et al (2025) Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. Front Neurol 16:1559118. https:\/\/doi.org\/10.3389\/fneur.2025.1559118","journal-title":"Front Neurol"},{"issue":"Suppl 1","key":"13425_CR37","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.4103\/0976-500X.120975","volume":"4","author":"M Ciriaco","year":"2013","unstructured":"Ciriaco M, Ventrice P, Russo G et al (2013) Corticosteroid-related central nervous system side effects. J Pharmacol Pharmacother 4(Suppl 1):S94\u2013S98. https:\/\/doi.org\/10.4103\/0976-500X.120975","journal-title":"J Pharmacol Pharmacother"},{"key":"13425_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101944","author":"J Andersen","year":"2025","unstructured":"Andersen J, Brilot F (2025) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): insights into pathogenesis and biomarkers of prognosis. Semin Immunol. https:\/\/doi.org\/10.1016\/j.smim.2025.101944","journal-title":"Semin Immunol"},{"issue":"10063","key":"13425_CR39","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1016\/S0140-6736(16)30654-7","volume":"388","author":"F McGill","year":"2016","unstructured":"McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T (2016) Acute bacterial meningitis in adults. Lancet 388(10063):3036\u20133047. https:\/\/doi.org\/10.1016\/S0140-6736(16)30654-7","journal-title":"Lancet"},{"key":"13425_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jneuroim.2017.12.019","volume":"315","author":"T Akaishi","year":"2018","unstructured":"Akaishi T, Takahashi T, Nakashima I (2018) Chloride imbalance between serum and CSF in the acute phase of neuromyelitis optica. J Neuroimmunol 315:45\u201349. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.12.019","journal-title":"J Neuroimmunol"},{"issue":"1","key":"13425_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01824-2","volume":"17","author":"S Jarius","year":"2020","unstructured":"Jarius S, Pellkofer H, Siebert N et al (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. part 1: results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 17(1):261. https:\/\/doi.org\/10.1186\/s12974-020-01824-2","journal-title":"J Neuroinflammation"},{"issue":"6","key":"13425_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1056\/NEJMc1111080","volume":"366","author":"LE Nigrovic","year":"2012","unstructured":"Nigrovic LE, Kimia AA, Shah SS, Neuman MI (2012) Relationship between cerebrospinal fluid glucose and serum glucose. N Engl J Med 366(6):576\u2013578. https:\/\/doi.org\/10.1056\/NEJMc1111080","journal-title":"N Engl J Med"},{"issue":"3","key":"13425_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/acn3.52310","volume":"12","author":"Y Said","year":"2025","unstructured":"Said Y, Filippatou A, Tran C et al (2025) Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay. Ann Clin Transl Neurol 12(3):556\u2013564. https:\/\/doi.org\/10.1002\/acn3.52310","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13425-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:03:17Z","timestamp":1761699797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13425-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["13425"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13425-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Bursa Uluda\u011f University (Approval 2024\u201314\/15).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participation"}}],"article-number":"680"}}